(Q38730155)

5 September 2017

title

Precision oncology: origins, optimism, and potential (English)

1 reference

5 September 2017

1

1 reference

5 September 2017

2

Tito Fojo

1 reference

5 September 2017

Michael Brada

3

1 reference

5 September 2017

publication date

1 February 2016

1 reference

Lancet Oncology Commission

5 September 2017

published in

1 reference

5 September 2017

volume

17

1 reference

5 September 2017

issue

2

1 reference

5 September 2017

page(s)

e81-e86

1 reference

ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

1 reference

7 January 2021

Cancer genes and the pathways they control

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

The consensus coding sequences of human breast and colorectal cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

Intratumor heterogeneity: evolution through space and time

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

Revealing selection in cancer using the predicted functional impact of cancer mutations. Application to nomination of cancer drivers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

Genome sequencing identifies a basis for everolimus sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

Characteristics of Exceptional or Super Responders to Cancer Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

Is there room for improvement in adverse event reporting in the era of targeted therapies?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

A decade of reversal: an analysis of 146 contradicted medical practices

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

The Frequency of Medical Reversal

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

Risks and benefits of phase 1 oncology trials, 1991 through 2002.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

A phase II study to evaluate the efficacy and toxicity of oxaliplatin in combination with gemcitabine in carcinoma of unknown primary

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

Proton therapy: the present and the future.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

Fractionated proton radiation therapy of chordoma and low-grade chondrosarcoma of the base of the skull

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

Stereotactic fractionated radiotherapy for chordomas and chondrosarcomas of the skull base.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

Chordomas and chondrosarcomas of the cranial base: results and follow-up of 60 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

Building a global consensus approach to chordoma: a position paper from the medical and patient community

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

Proton therapy for tumors of the skull base

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

Global patterns of cancer incidence and mortality rates and trends

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900620-8

7 January 2021

10.1016/S1470-2045(15)00620-8

Identifiers

DOI

1 reference

5 September 2017

1 reference